Payers and the Inflation Reduction Act

A view into how twelve large national and regional payers are preparing for the IRA, and what their planning means for the future of pharmaceutical forecasting

Overview

The Inflation Reduction Act introduces the most significant changes to U.S. drug pricing in decades, with Medicare price negotiations, a $2,000 out-of-pocket cap, and a redesigned Part D structure all reshaping the commercial environment. We share findings from interviews with medical and pharmacy directors at twelve large national and regional payers, capturing how plans are preparing for the changes ahead. The paper covers payer expectations on pricing, the response to the Part D redesign, anticipated spillover into commercial business, and the implications for pharmaceutical forecasts.

Key Takeaways

• Payers are taking a wait-and-see approach to price negotiations but are actively modeling tighter utilization management in response to the Part D redesign
• Most payers expect commercial prices to decrease as plans harmonize formularies across Medicare and commercial books
• Forecasts in the IRA environment will need more architectural detail, more frequent payer research, and the flexibility to support scenario analysis as strategies evolve